罕见EGFR突变:奥希替尼一线真实世界实践疗效的国际病例系列研究(UNICORN)
这项多中心回顾性研究纳入60例携带罕见EGFR突变(排除20外显子插入)的转移性非小细胞肺癌患者,以奥希替尼作为首个EGFR抑制剂治疗。总体客观缓解率为61%,中位无进展生存期9.5个月,中位缓解持续时间17.4个月,中位总生存期24.5个月;研究还报告了颅内客观缓解率及耐药后突变谱。
要点
- 总体客观缓解率61%,中位无进展生存期9.5个月,中位缓解持续时间17.4个月,中位总生存期24.5个月。
- L861Q组客观缓解率80%、中位无进展生存期16个月;G719X组分别为47%和8.8个月;新发T790M组分别为44%和12.7个月。
- 13例可评估脑转移患者颅内客观缓解率为46%;14例再活检中识别出C797S、D585Y、E709K等耐药相关改变。
核心结论
- 奥希替尼在罕见EGFR突变转移性非小细胞肺癌中显示出全身及颅内疾病控制活性,并识别出多种耐药机制。
- 作者称本研究为同类研究中最大的数据集。
研究设计与样本
- 多中心回顾性研究,纳入60例携带罕见EGFR突变(排除20外显子插入)的转移性非小细胞肺癌患者,来自22个中心、9个国家。
- 患者以奥希替尼作为首个EGFR抑制剂治疗;疗效由研究者按实体瘤疗效评价标准及神经肿瘤脑转移疗效评估标准评价。
主要发现
- 总人群客观缓解率61%,中位无进展生存期9.5个月,中位缓解持续时间17.4个月,中位总生存期24.5个月。
- 无合并常见突变或T790M者(A组,n=44)客观缓解率60%,中位无进展生存期8.6个月,中位缓解持续时间11个月。
- G719X组客观缓解率47%,中位无进展生存期8.8个月,中位缓解持续时间9.1个月;L861Q组分别为80%、16个月、16个月;新发T790M组分别为44%、12.7个月、46.2个月。
- 合并常见突变的复合EGFR突变较单纯罕见EGFR突变预后更好;13例可评估脑转移患者颅内客观缓解率46%。
- 14例再活检中,4例出现附加EGFR突变(C797S、D585Y、E709K),3例新发TP53突变,1例c-Met扩增,1例PIK3CA突变,1例神经内分泌转化。
关键数值与推荐
- 客观缓解率61%,中位无进展生存期9.5个月,中位缓解持续时间17.4个月,中位总生存期24.5个月(总人群)。
- A组(n=44)客观缓解率60%,中位无进展生存期8.6个月,中位缓解持续时间11个月。
- G719X组客观缓解率47%、中位无进展生存期8.8个月、中位缓解持续时间9.1个月;L861Q组80%、16个月、16个月;新发T790M组44%、12.7个月、46.2个月。
- 可评估脑转移患者(n=13)颅内客观缓解率46%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Approximately 10% of EGFR mutations (EGFRmuts) are uncommon (ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with ucEGFRmuts. METHODS: This is a multicenter, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC treated with osimertinib as first EGFR inhibitor. The Response Evaluation Criteria in Solid Tumors and response assessment in neuro-oncology brain metastases brain objective response rate (ORR) were evaluated by the investigators. Median progression-free survival (mPFS), median overall survival, and median duration of response (mDOR) were calculated from osimertinib initiation. Mutations found at resistance were collected. RESULTS: A total of 60 patients were included (22 centers, nine countries), with median age of 64 years, 75% females, and 83% Caucasian. The largest subgroups were G719X (30%), L861Q (20%), and de novo Thr790Met (T790M) (15%). The ORR was 61%, mPFS 9.5 months, mDOR 17.4 months, and median overall survival 24.5 months. Regarding patients with no concurrent common mutations or T790M (group A, n = 44), ORR was 60%, mPFS 8.6 months, and mDOR 11 months. For G719X, ORR was 47%, mPFS 8.8 months, and mDOR 9.1 months. For L861Q, ORR was 80%, mPFS 16 months, and mDOR 16 months. For de novo T790M, ORR was 44%, mPFS 12.7 months, and mDOR 46.2 months. Compound EGFRmut including common mutations had better outcome compared with only ucEGFRmut. For 13 patients with a response assessment in neuro-oncology brain metastases-evaluable brain metastases, brain ORR was 46%. For 14 patients, rebiopsy results were analyzed: four patients with additional EGFR mutation (C797S, D585Y, E709K), three with new TP53 mutation, one with c-Met amplification, one with PIK3CA mutation, and one with neuroendocrine transformation. CONCLUSIONS: Osimertinib was found to have an activity in ucEGFRmut with a high rate of disease control systemically and intracranially. Several resistance mechanisms were identified. This report comprises, to the best of our knowledge, the largest data set of its kind.
引用
- Bar J, Peled N, Schokrpur S, et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J Thorac Oncol. 2022. PMID: 36307041. doi:10.1016/j.jtho.2022.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。